1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Applied BioCode Corporation

Applied BioCode Corporation

6598.TW
Applied BioCode CorporationTW flagTaiwan Stock Exchange
23.25
TWD
+0.20
- -
2.39BMarket Cap

Total Valuation

Applied BioCode Corporation carries a market capitalization of 2.39B, placing it among publicly traded companies globally. Its enterprise value stands at 1.74B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.39B
Enterprise Value1.74B

Share Statistics

Applied BioCode Corporation currently has 102.81M shares outstanding.

Shares Outstanding102.81M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 4.74, and the price-to-book ratio stands at 3.69.

PE RatioN/A
PS Ratio4.74
PB Ratio3.69
P/TBV Ratio3.50
P/FCF Ratio-10.34
P/OCF Ratio-9.94

Enterprise Valuation

EV / Sales3.67
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Applied BioCode Corporation maintains a current ratio of 6.78, meaning it holds 6.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.26, indicating elevated leverage, while an interest coverage ratio of -140.40 demonstrates limited ability to service its debt obligations.

Current Ratio6.78
Quick Ratio4.50
Debt / Equity9.26
Debt / EBITDA-0.27
Interest Coverage-140.40

Financial Efficiency

Return on Equity (ROE)-33.98
Return on Assets (ROA)-18.06
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.24

Taxes

Income Tax79,000.00
Effective Tax RateN/A

Stock Price Statistics

Applied BioCode Corporation's stock has gained approximately 17.42424% over the past 52 weeks. The 50-day moving average sits at 23.63, while the 200-day moving average is 23.19.

Beta (5Y)N/A
52-Week Price Change17.42424%
50-Day Moving Average23.63
200-Day Moving Average23.19
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Applied BioCode Corporation generated 475.20M in revenue and converted that into -201.20M in net income, yielding earnings per share of -1.97. EBITDA reached -222.82M, while operating income came in at -222.82M.

Revenue475.20M
Gross Profit260.89M
Operating Income-222.82M
Pretax Income-201.12M
Net Income-201.20M
EBITDA-222.82M
EBIT-222.82M
Earnings Per Share (EPS)-1.97

Balance Sheet

Applied BioCode Corporation holds 569.59M in cash and equivalents against 59.56M in total debt, resulting in a net debt position of -464.79M. Total book value stands at 610.30M, with working capital of 731.92M providing operational flexibility.

Cash & Cash Equivalents569.59M
Total Debt59.56M
Net Debt-464.79M
Equity (Book Value)610.30M
Book Value Per Share5.96
Working Capital731.92M

Cash Flow

Applied BioCode Corporation produced -226.64M in operating cash flow over the past twelve months. After subtracting -8.82M in capital expenditures, free cash flow totaled -235.46M - equivalent to -2.30 per share.

Operating Cash Flow-226.64M
Capital Expenditures-8.82M
Free Cash Flow-235.46M
FCF Per Share-2.30

Margins

Applied BioCode Corporation operates with a gross margin of 54.90, reflecting its pricing power and cost economics. The operating margin of -46.89 and net profit margin of -42.34 provide insight into operational efficiency.

Gross Margin54.90
Operating Margin-46.89
Pretax Margin-42.32
Profit Margin-42.34
EBITDA Margin-46.89

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield0.84
FCF Yield-9.67

Stock Splits

Applied BioCode Corporation's most recent stock split took place on July 2, 2024 with a 500:529 split ratio.

Last Split Date7/2/2024
Split Ratio500:529

Scores

Applied BioCode Corporation posts an Altman Z-Score of 3.69, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.69